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AstrocytesNeurodegenerative diseases are characterized by progressive degeneration of selective neurones in the nervous
system, but the underlying mechanisms involved in neuroprotection and neurodegeneration remain unclear.
Dysfunction of the ubiquitin proteasome system is one of the proposed hypotheses for the cause and progression
of neuronal loss.We have performed quantitative two-dimensionalﬂuorescence difference in-gel electrophoresis
combined with peptide mass ﬁngerprinting to reveal proteome changes associated with neurodegeneration
following 26S proteasomal depletion in mouse forebrain neurones. Differentially expressed proteins were
validated by Western blotting, biochemical assays and immunohistochemistry. Of signiﬁcance was
increased expression of the antioxidant enzyme peroxiredoxin 6 (PRDX6) in astrocytes, associated with
oxidative stress. Interestingly, PRDX6 is a bifunctional enzyme with antioxidant peroxidase and phospholipase
A2 (PLA2) activities. The PLA2 activity of PRDX6was also increased following 26S proteasomal depletion andmay
be involved in neuroprotective or neurodegenerative mechanisms. This is the ﬁrst in vivo report of oxidative
stress caused directly by neuronal proteasome dysfunction in the mammalian brain. The results contribute to
understanding neuronal–glial interactions in disease pathogenesis, provide an in vivo link between prominent
disease hypotheses and importantly, are of relevance to a heterogeneous spectrum of neurodegenerative
diseases.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Neurodegenerative diseases are characterized by the progressive
degeneration of selective neurones of the nervous system. Abnormal
protein aggregation, impaired protein degradation, mitochondrial
dysfunction and oxidative stress are key hypotheses for cause and
progression of major human neurodegenerative diseases, including
Alzheimer's disease (AD) and Parkinson's disease (PD) [1–3]. Attention
has also turned to the contribution of glial cells to neurodegeneration
[4], but the underlying mechanisms involved in neuroprotection and
neurodegeneration in the nervous system remain unclear.
The ubiquitin proteasome system (UPS) is the major intracellular
pathway for regulated degradation of unwanted proteins and central
to normal cellular homeostasis [5]. A sequence of enzymes covalently
attach polyubiquitin chains to unwanted proteins as a signal forences, University of Nottingham,
44 1158230512.
Bedford).
B.V. Open access under CC BY-NC-ND degradation by the 26S proteasome. Studies in human brain and disease
models have implicated dysfunction of the UPS in the pathological
changes that lead to neurodegeneration [6–9]. Ubiquitin-positive
protein inclusions are a common feature of human neurodegenerative
diseases [6]. Also, in PD and dementia with Lewy bodies (DLB) patients,
altered proteasome activity and subunit expression has been reported
[7]. In a signiﬁcant study, we showed that genetic depletion of 26S
proteasomes in mouse brain neurones caused neurodegeneration and
the formation of protein inclusions resembling human pale bodies, the
precursor of Lewy bodies, providing a compelling link between
UPS-mediated protein degradation and neurodegeneration [10].
Proteomic studies are of considerable interest to identify
much-needed novel pathogenic mechanisms connected to neurode-
generative disease. There are inherent difﬁculties with a study of a
mixture of cell-types in the brain, but it is essential to investigate
in vivo models to identify the importance of neuronal–glial cellular
interactions during disease development that are not revealed in
studies of cell lines composed of a single clonal cell-type. We have
employed a quantitative two-dimensional ﬂuorescence difference
in-gel electrophoresis (2D-DIGE) proteomic approach to reveal
proteome changes associated with cortical neurodegeneration
following 26S proteasomal depletion in our unique mouse model.license.
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alternative approaches, namely 1D and 2D Western blotting as well
as biochemical and immunohistochemical investigations to further
understand their signiﬁcance. The results show new information
linking UPS dysfunction to oxidative stress in the brain in vivo and
the importance of understanding neuronal–glial interactions during
disease progression.
2. Materials and methods
2.1. 26S proteasomal depletion mouse model
Neurone-speciﬁc 26S proteasome-depletedmicewere createdusing
Cre/loxP conditional gene targeting as described in detail previously
[10]. For forebrain, including cortex, neurone-speciﬁc inactivation of
Psmc1, Cre recombinasewas expressed under the control of the calcium
calmodulin-dependent protein kinase IIα promoter (Psmc1ﬂ/ﬂ;
CaMKIIα-Cre) [10]. CaMKIIα is expressed in post-mitotic neurones
from approximately post-natal week 2 [11,12]. Appropriate litter-
mate mice were used as controls.
All procedures were carried out under personal and project licenses
granted by theUKHomeOfﬁce in accordancewith theAnimals (Scientiﬁc
Procedures) Act 1986 and with ethical approval from the University of
Nottingham Ethical Review Committee.
2.2. 2D ﬂuorescence difference in-gel electrophoresis (2D-DIGE)
Mouse cortex was homogenized in lysis buffer containing 30 mM
Tris–HCl pH 8.8, 8 MUrea and 4% (w/v) CHAPS, followed by centrifuga-
tion at 20,000 g for 5 min at 4 °C and collection of supernatant. Protein
estimation used the Bio-Rad (Bradford) protein assay kit. CyDye
labeling was performed according to the manufacturer's instructions
(GE Healthcare) and incorporating a dye swap. 15 μg of each sample
was labeled with Cy3 and Cy5, and a pooled sample was labeled with
Cy2 containing equal amounts of all samples as an internal standard.
10 mM lysine was used to stop labeling. First dimension isoelectric
focusing (IEF) used a Bio-Rad Protein IEF Cell and 7 cm 3–10
non-linear pH gradient IPG strips (Bio-Rad). Strips were passively
rehydrated for 1 h, actively rehydrated for 13 h and 40 min at 50 V
followed by IEF (250 V for 20 min linear, 4000 V for 2 h linear,
4000 V for 10,000 V/h rapid). The strips were incubated in 2% (w/v)
dithiothreitol in equilibration buffer [50 mM Tris–HCl pH 8.8, 6 M
Urea, 2% (w/v) sodium dodecyl sulfate (SDS) and 20% (v/v) glycerol]
and then 2.5% (w/v) iodoacetamide in equilibration buffer for 15 min
each. Strips were placed on top of 12–18% gradient SDS-PAGE resolving
gels for the second dimension. A Fujiﬁlm FLA-5100 scanner was used to
scan each gel at the corresponding wavelengths to the CyDyes. Images
were analyzed using SameSpots software (Progenesis) with a 1.2-fold
change set as the cut off value and ANOVA (P b 0.05).
2.3. Mass spectrometry analysis
For identiﬁcation of protein spots, gels were either silver (GE
Healthcare) or Coomassie blue (Cheshire Sciences) stained using a
mass spectrometry-compatible protocol. Spots were excised from
the gel manually and washed three times with 50 μL of acetonitrile
(ACN)/25 mM NH4HCO3 (2:1) for 15 min each followed by 50 μL
of 25 mM NH4HCO3 for 10 min. Gel pieces were then air dried for
15 min and rehydrated in 5 μL of 12.5 ng/μL sequencing grade tryp-
sin (Promega) on ice for 20 min. 5 μl of 25 mM NH4HCO3 was added
to each tube and incubated at 37 °C for 4 h. Tryptic digests were col-
lected, dried in a vacuum concentrator (Eppendorf) and 2 μl of 50%
(v/v) ACN/0.1% (v/v) triﬂuoroacetic acid (TFA) was added to each
tube. Finally, 0.5 μL of sample was transferred to the MALDI plate
followed by 0.5 μL of 10 mg (w/v) α-cyano-4-hydroxycinnamic
acid matrix (LaserBio Laboratories) in 50% (v/v) ACN/0.1% (v/v)TFA. Peptide mass ﬁngerprints were generated using a MALDI-TOF
mass spectrometer (Bruker Daltonics Ultraﬂex III MALDI-TOFTOF).
Proteins were identiﬁed using the Mascot search engine (http://www.
matrixscience.com); stating “Mus musculus” species, carbamidomethyl
ﬁxed and oxidized methionine as variable modiﬁcations and 100 ppm
peptide tolerance. Positive identity was given by scores over 56 (com-
paring Swiss-Prot database) and their molecular mass and pI were
compared to the position of the spot on the 2D gel.2.4. Western blot analysis
Mouse cortex was homogenized as described in 2D-DIGE. 50–100 μg
was mixed with 2× reducing sample buffer [150 mM Tris–HCl pH 6.8,
8 M Urea, 10% (v/v) SDS, 20% (v/v) glycerol, 10% (v/v) mercaptoethanol,
3% (w/v) dithiothreitol, 0.1% (w/v) bromophenol blue]. Proteins were
separated using 12% SDS-PAGE and transferred to nitrocellulose
membrane. Blocking was for 1 h in 5% (w/v) Marvel in Tris-buffered
saline containing 0.1% (v/v) Tween 20. Incubation in primary and
corresponding horseradish peroxidase-conjugated secondary antibodies
(Sigma) was overnight at 4 °C and for 1 h at room temperature respec-
tively in blocking solution. The primary antibodies used were: 1:1000
vimentin (GeneTex), peroxiredoxin 6 (GeneTex), glucose-regulated
protein (Cell Signaling), protein disulphide isomerase (GeneTex),
CCAAT-enhancer-binding protein homologous protein (Cell Signaling)
and glial ﬁbrillary acidic protein (Sigma); 1:500 fumerate hydratase
(GeneTex); 1:250 stathmin (GeneTex); 1:200 X-box binding protein
(Santa Cruz). Proteinsweredetectedusing enhanced chemiluminescence
(Pierce). The band intensity was calculated with Quantity One 1-D anal-
ysis Software and/or Aida. For 2D Western blot analysis, samples were
separated as described in 2D-DIGE and following the second dimension
processed to Western blotting as described here.2.5. Reactive oxygen species assay
Levels of reactive oxygen species were examined using the
2′,7′-dichloroﬂuorescein diacetate — cellular reactive oxygen species
detection assay kit (abcam) according to themanufacturer's instructions.
Detection used ﬂuorescent spectroscopy with excitation and emission of
485 nm and 520 nm respectively.2.6. Lipid peroxidation
Malondialdehyde (MDA) concentration was determined as an indi-
cator of lipid peroxidation products based on the method of Erdelmeier
et al. [13]. Mouse cortexwas homogenized in 5 mMbutylated hydroxy-
toluene in 20 mM phosphate buffer pH 7.4, followed by centrifugation
at 3000 g for 10 min at 4 °C. Protein estimation used the Bio-Rad
(Bradford) protein assay kit. 300 μl (9.5 μg/μl) was hydrolyzed
using HCl pH 1–2 and incubated at 60 °C for 80 min. 60 μl of sample
was mixed with 195 μl of 10.3 mM N-methyl-2-phenylindol in 3:1
(v/v) acetonitrile:methanol and then 45 μl of concentrated HCl,
incubated at 45 °C for 60 min and centrifuged at 15,000 g for
10 min to clarify. Absorbance was measured spectrophotometrically
at 586 nm. Concentration of malondialdehyde (μM/mg protein) was
calculated using 1,1,3,3-tetramethoxypropane as a standard.2.7. Phospholipase A2 assay
Phospholipase A2 (PLA2) activity (U/ml/mg protein)was determined
using EnzChek Phospholipase A2 Assay kit (Invitrogen) according to the
manufacturer's instructions. Detection used ﬂuorescent spectroscopy
with excitation and emission of 485 nm and 520 nm respectively.
MJ33 inhibitor was used at 3 mol% based on previous reports [14,15].
Fig. 1. Representative 2D gel image of mouse brain cortex homogenate labeled with
Cy5 dye and differentially-expressed protein spots between 26S proteasome-depleted
and control mouse cortices highlighted (spots 1–24). Numbered spots showed
≥1.2-fold change with statistical signiﬁcance (ANOVA p b 0.05). Spots 1–16 were
identiﬁed by peptide mass ﬁngerprinting (Supplementary Table 1).
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Protein carbonyl content (nM/mg protein)was determined utilizing
the 2,4-dinitrophenylhydrazine (DNPH) reaction following Cayman's
Protein Carbonyl Colorimetric AssayKit according to themanufacturer's
instructions. Absorbance was measured spectrophotometrically at
375 nm.
2.9. Immunohistochemistry
Mice were perfusion-ﬁxed with 0.9% saline followed by 4% parafor-
maldehyde in phosphate buffered saline pH 7.4. The brains were then
processed to parafﬁn with chloroform as the clearing agent. Immunohis-
tochemistry was performed as directed in Vector Laboratories M.O.M
Immunodetection [GFAP (Sigma)] or Vectastain Elite Rabbit IgG [PRDX6
(GeneTex) and MAP2 (abcam)] ABC kits using 0.01 M citrate buffer
containing 0.05% Tween-20 pH 6 for antigen retrieval and appropriate
ﬂuorescently-conjugated secondary antibodies.
2.10. Statistical analysis
Results are expressed as mean average ± SEM. Statistical differ-
ences were analyzed by ANOVA and Student's t-test with signiﬁcance
set as indicated.
3. Results
3.1. 26S proteasomal depletion mouse model of neurodegeneration
Generation of neurone-speciﬁc 26S proteasome-depleted mice has
been described in detail previously [10]. To summarize, the Cre/loxP
system spatially restricts inactivation of an essential subunit of the 19S
regulatory particle of the 26S proteasome, ATPase Psmc1. PSMC1 is
necessary for the assembly and activity of the 26S proteasome [10].
For forebrain neurone-speciﬁc inactivation of Psmc1, including cortex,
ﬂoxed Psmc1mice were crossed with mice expressing Cre recombinase
under the control of the calcium calmodulin-dependent protein kinase
IIα promoter (Psmc1ﬂ/ﬂ;CaMKIIα-Cre). CaMKIIα is expressed in
post-mitotic neurones from approximately post-natal week 2. We
previously showed that 26S proteasomal depletion in mouse cortical
brain neurones caused neurodegeneration and the formation of
intraneuronal inclusion bodies accompanied by reactive gliosis at
6 weeks of age [10]. The study here investigates proteomic changes
accompanying neurodegeneration in the mouse cortex.
3.2. Differentially-expressed proteins in 26S proteasome-depleted cortex
Cortices from individual 6 week-old 26S proteasome-depleted and
control (n = 4) mice were compared using 2D-DIGE proteomic analy-
sis and Progenesis SameSpots to identify differentially-expressed
proteins. Fig. 1 shows a representative 2D gel image. The expression
level of 24 spots showed statistically signiﬁcant changes between
26S proteasome-depleted and control animals (≥1.2-fold, ANOVA
p b 0.05). Supplementary Table 1 lists the 19 proteins that were
identiﬁed by peptide mass ﬁngerprinting. The 2D-DIGE results and
protein identiﬁcations were validated by Western blot analysis of
selected differentially-expressed proteins based on antibody availabili-
ty. We conﬁrmed by 1D Western blotting that expression of glial
ﬁbrillary acidic protein (GFAP; Fig. 1, spot 2), vimentin (VIME; Fig. 1,
spot 1) and peroxiredoxin 6 (PRDX6; Fig. 1, spot 10) was signiﬁcantly
increased while mitochondrial fumarate hydratase (FUMH; Fig. 1,
spot 4) and stathmin (STMN1; Fig. 1, spot 11) were signiﬁcantly
decreased in 26S proteasome-depleted vs. control cortex consistent
with the 2D-DIGE analysis (Fig. 2). GFAP and VIME are associated
with the intermediate ﬁlament system in astrocytes and their
up-regulation is a hallmark of astrocyte activation and the resultingreactive gliosis [16]. This conﬁrms our previously reported reactive
astrogliosis by GFAP immunostaining of cortical brain sections following
neuronal 26S proteasomal depletion [10]. PRDX6 has a well-known role
as an antioxidant enzyme and its up-regulation in the cortex following
26S proteasomal depletion is suggestive of oxidative stress [17–22].
FUMH is a key enzyme of the tricarboxylic acid (TCA) cycle and
STMN1 has an important function in microtubule dynamics [23].
2D gel electrophoresis can separate isoforms of the same protein,
whereas 1D Western blotting provides a single band of total protein.
Fig. 3 shows differential expression of GFAP isoforms in 6 week-old
mice using 2D Western blot analysis. Two predominant isoforms of
GFAP were detected in the control and 26S proteasome-depleted
mouse cortices (Fig. 3; spots 1 and 2). Four additional GFAP isoforms
were detected in the 26S proteasome-depleted cortex (Fig. 3; spots
3–6). Interestingly, GFAP was also identiﬁed in 2D-DIGE spot 9
(Fig. 1 and Supplementary Table 1) that may correspond to spot 5
or 6 in Fig. 3. We cannot exclude that the novel isoforms of GFAP
detected in the 26S proteasome-depleted cortex may be present in
the control cortex, but below the level of detection by this approach.
GFAP isoforms may be associated with astrocyte subtypes that have
speciﬁc functions and neuropathological conditions in the brain
[24,25]. Alternatively, spots 5 and 6 may be GFAP protein breakdown
products [26].
3.3. Neuronal 26S proteasomal depletion causes oxidative stress
Since oxidative stress is a pivotal factor in neuronal death in neuro-
degenerative diseases, we further investigated the antioxidant enzyme
PRDX6 and oxidative stress in the mouse cortex following 26S
proteasomal depletion.
To investigate the levels of reactive oxygen species (ROS) in
26S proteasome-depleted and control mouse cortices we used
2′,7′-dichloroﬂuorescein diacetate ﬂuorogenic dye. This is the most
widely used assay for measuring oxidative stress [27]. The levels of
ROS were signiﬁcantly increased in 26S proteasome-depleted corti-
ces at 2 and half weeks of age (t-test p b 0.05; Fig. 4A). Because
CaMKIIα is expressed in cortical neurones from approximately
postnatal week 2, the data indicate that the ensuing loss of PSMC1
and 26S proteasome activity causes oxidative stress. There was no
signiﬁcant difference in ROS levels between 26S proteasome-depleted
and control mouse cortices at 3 weeks-old (Fig. 4B). At 4 and 6 weeks
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Fig. 2. Validation and quantitation of identiﬁed protein changes following 26S proteasomal depletion in mouse cortex. 1D Western blot analysis of total cortical homogenates from
6 week-old control and 26S proteasome-depleted (Psmc1ﬂ/ﬂ;CaMKIIα-Cre) mice for GFAP, VIME, PRDX6, FUMH and STMN1. A representative β-actin loading control is shown; this
was performed for each Western blot. (B–F) Densitometry used QuantityOne software. Values were normalized to β-actin and represented as % vs. controls. Error bars represent
SEM. n ≥ 3, *p b 0.05, **p b 0.01 (Student's t-test).
1933J. Elkharaz et al. / Biochimica et Biophysica Acta 1832 (2013) 1930–1938of age there was a signiﬁcant decrease in the levels of ROS in 26S
proteasome-depleted cortices compared to controls (t-test p b 0.01;
Fig. 4C and D). Linear regression analysis showed a signiﬁcant correla-
tion between age and the levels of ROS in 26S proteasome-depleted
cortex (p b 0.05; Fig. 4E). There was also a signiﬁcant correlation
between age and the levels of PRDX6 protein expression in 26S
proteasome-depleted cortex between 2 and 6 weeks-old (p b 0.01;
Fig. 4E). Importantly, there was an inverse relationship between the
levels of PRDX6 protein expression and ROS in 26S proteasome-GFAP
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2
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Fig. 3. Protein isoform expression of GFAP revealed by 2D Western blotting of control and
GFAP isoforms.depleted mouse cortex with increasing age, indicative of an antioxidant
response of PRDX6 (Fig. 4E).
3.4. Neuronal 26S proteasomal depletion causes increased lipid peroxidation
High polyunsaturated fatty acid content makes the brain particu-
larly susceptible to oxidative stress-associated lipid damage. Also,
lipid peroxidation is known to be an autocatalytic process, amplifying
the destructive effects of the initial free radical [28,29]. Quantitation1
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1934 J. Elkharaz et al. / Biochimica et Biophysica Acta 1832 (2013) 1930–1938of malondialdehyde (MDA), a toxic secondary product of membrane
lipid peroxidation, in cortical tissue homogenates between 4 and
6 weeks of age identiﬁed signiﬁcantly increased levels of MDA in 5
and 6 week-old 26S proteasome-depleted mice compared to controls
(t-test p b 0.01; Fig. 5A–C), indicating that lipid oxidation is increased
following neuronal 26S proteasomal depletion.
Protein carbonyls are hallmarks of the oxidative status of pro-
teins. Therefore, to further investigate oxidative stress, we evaluated
carbonyl content spectrophotometrically using a reaction with
2,4-dinitrophenylhydrazine in mouse cortical tissue homogenates.No signiﬁcant difference in the levels of protein carbonyls was ob-
served between 26S proteasome-depleted and control mouse corti-
ces at 6 weeks-old (Supplementary Fig. 1).
3.5. Increased phospholipase A2 activity in 26S proteasome-depleted
cortex
Interestingly, PRDX6 is a bifunctional enzyme with peroxidase and
phospholipase A2 (PLA2) activities [30]. The PLA2 activity of PRDX6
has not been studied aswidely as the peroxidase-associated antioxidant
properties. Quantitation of PLA2 activity in 26S proteasome-depleted and
control cortical homogenates between 4 and 6 weeks of age showed sig-
niﬁcantly increased activity in the 6 week-old 26S proteasome-depleted
mouse cortex (t-test p b 0.01; Fig. 5D–F). The chemical inhibitor MJ33
that has previously been shown to have some (although not total)
speciﬁcity for PRDX6 PLA2 activity [14,15] signiﬁcantly decreased PLA2
activity in 26S proteasome-depleted cortex, suggesting that some of the
PLA2 activity was associated with PRDX6 (Fig. 5F).
3.6. Astrocytic localization of PRDX6
To investigate the cellular localization of PRDX6 we performed
double immunoﬂuorescent labeling of brain sections with PRDX6 and
GFAP or 200 kD neuroﬁlament heavy chain (NF-H) for astrocytes and
neurones respectively (Fig. 6 and Supplementary Fig. 2). PRDX6
immunolabeled cells with the characteristic morphology of astrocytes
in control and 26S proteasome-depleted cortices from 6 week-old
mice (Fig. 6). Double-labeling with GFAP conﬁrmed the localization of
PRDX6 in astrocytes in the 26S proteasome-depleted mice (Fig. 6;
right-hand panel). GFAP is themost widely usedmarker for immunohis-
tochemical identiﬁcation of astrocytes and labels reactive astrocytes that
are responding to central nervous system (CNS) damage, but it is
recognized that not all non-reactive astrocytes in the healthy CNS
are identiﬁed by GFAP [31]. Therefore, PRDX6 expression in the
control mouse brain is in non-reactive astrocytes that are not
immunohistochemically labeled by GFAP (Fig. 6; left-hand panel).
Importantly, we noted a much higher diffuse PRDX6 staining in the
26S proteasome-depleted cortical brain sections compared to the
control (Fig. 6; compare i and ii), suggesting PRDX6 may be secreted
by activated astrocytes in response to the neuronal changes. The
expression of PRDX6 did not co-localize with NF-H in mouse cortical
neurones (Supplementary Fig. 2).
4. Discussion
Proteomic studies of human post-mortem brain and disease models
are of considerable interest to understand pathogenic mechanisms
connected to neurodegenerative disease. This study has identiﬁed and
validated several differentially-expressed proteins accompanying
neurodegeneration in the mouse cortex following neuronal 26S
proteasomal depletion. Among these, the antioxidant enzyme PRDX6
was signiﬁcantly increased. Since oxidative stress is a pivotal factor in
human neurodegenerative diseases [32,33], supported by animal and
cellular models [33–35], we further investigated PRDX6 and oxidative
stress in the 26S proteasome-depleted mouse cortex.
Here we have shown a signiﬁcant inverse relationship between the
levels of PRDX6 protein expression and ROS following 26S proteasomal
depletion in mouse cortical neurones, indicative of oxidative stress and
an antioxidant response of PRDX6. Lipid peroxidation was also
signiﬁcantly increased in the cortex of 26S proteasome-depleted mice.
Similar to the other PRDXs and glutathione peroxidase family, PRDX6
can reduce hydrogen peroxide and short chain hydroperoxides, but
PRDX6 can also directly bind and reduce phospholipid hydroperoxides
[36,37]. This characteristic plays an important role in its antioxidant
defense [19,20]. Studies in cell and mouse models demonstrate that
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sensitivity or resistance to oxidant stress respectively [17–22].
PRDX6 is a bifunctional enzyme with peroxidase and PLA2 activities
[30]. Increased PLA2 activity in 26S proteasome-depleted cortex corre-
lates with increased PRDX6 expression. Given previous studies have
shown that the PLA2 activity of PRDX6 is sensitive to MJ33 [14,15], we
propose that the decreased PLA2 activity in the presence of MJ33 is
partly attributable to PRDX6. However, we recognize that MJ33 is not
totally speciﬁc for PRDX6 and that other phospholipases that have
not been investigated in this study presumably explain the MJ33-
insensitive PLA2 activity [38].
The PLA2 activity of PRDX6 has been associated with several cellular
functions. PLA2 enzyme activity liberates both a free fatty acid and
lysophosphatidylcholine from phosphatidylcholine substrates and has
been implicated in oxidative stress-induced apoptosis and inﬂamma-
tion [39–42]. Importantly, a recent study in pulmonary microvascular
endothelial cells suggested that the PLA2 activity of PRDX6 may also
play a role in antioxidant protection provided by PRDX6 [43].
The cellular distribution of PRDX6 in our mouse model is similar to
previous studies in mouse and human brain showing expression of
PRDX6 mainly in astrocytes [44–49]. A study in mouse brain neural
cell types showed differential expression patterns of the sixmammalian
isoforms of the PRDX family and only PRDX6 was found in astrocytes,
which may be indicative of a speciﬁc role in their function [46]. Impor-
tantly, an increase in PRDX6 and the number and staining intensity of
PRDX6-positive astrocytes has been described in human brain regions
affected in AD, PD and DLB, as well as other neurodegenerative disease
mouse models [44,45,47,49,50]. Since oxidative stress is regarded as a
fundamental process in the events that lead to neurodegeneration, the
antioxidant function of PRDX6 may play an important neuroprotective
response of the astrocyte [32,51,52]. Further support for PRDX6 in thiscontext was shown in parkin-deﬁcient mice, where PRDX6 was
downregulated [53].
We also noted a much higher diffuse PRDX6 staining in the 26S
proteasome-depleted cortical brain sections compared to the control,
suggesting PRDX6 may be secreted by activated astrocytes. This is
supported by previous studies that have suggested that this enzyme
may be a secreted protein [44,54]. Evidence suggests PRDX6 is
present at very low levels in neurones and an early study in PD and
DLB disease brains demonstrated the presence of PRDX6 in Lewy
bodies [44,46–49]. However, PRDX6 expression was not detectable
in neurones or inclusion bodies in our mouse model.
This is the ﬁrst in vivo report of oxidative stress caused directly by
neuronal 26S proteasome dysfunction in the mammalian brain. Our
ﬁndings are supported by cellular studies using chemical proteasome
inhibitors [55–57]. Various antioxidant defenses have also been dem-
onstrated in response to proteasome inhibitor oxidative stress [57],
but PRDX6 has not been described previously and most likely because
studies were not focused on the brain. Since the high polyunsaturated
fatty acid content makes the brain particularly susceptible to lipid
peroxidation, the unique ability of PRDX6 to reduce phospholipid
hydroperoxides may play an important role in antioxidant protection
in the brain.
Increased astrocytic PRDX6 expression was associated with de-
creased levels of ROS, and together with the presence of oxidative
stress, supports an antioxidant neuroprotective role of astrogliosis
in response to neurodegeneration caused by 26S proteasome deple-
tion in mouse brain neurones. However, the astrocytic network has
a wide range of activities that can be both beneﬁcial and detrimental
such as energy metabolism and the release of inﬂammatory mole-
cules respectively [31,58]. We emphasize that the PLA2 activity of
PRDX6 may also be involved in the production of further mediators
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Fig. 6. Astrocytic localization of PRDX6 in the mouse cortex. Double immunoﬂuorescent
labeling of cortical brain sections from control and 26S proteasome-depleted (Psmc1ﬂ/ﬂ;
CaMKIIα-Cre) 6 week-old mice with GFAP (green) and PRDX6 (red). DAPI (blue) was
used as a ﬂuorescent nuclear counterstain. Enlarged views of the boxed areas are shown
(zoom). Note much higher diffuse PRDX6 staining in the 26S proteasome-depleted
cortical brain sections in addition to the more focused staining in astrocytes (compare i
and ii). Scale bar, 50 μm.
1936 J. Elkharaz et al. / Biochimica et Biophysica Acta 1832 (2013) 1930–1938related to cellular signaling functions that may be protective or dele-
terious in the progressive neuronal loss.
The intercellular signaling molecule(s) and mechanism(s) that
modulate reactive astrogliosis in response to neurodegeneration fol-
lowing 26S proteasomal depletion in neurones will require further
study. Diverse molecules have been suggested that can be released
by all central nervous system cell-types, including ROS [58,59]. In-
terestingly, we report here that mitochondrial FUMH, a key enzyme
of the TCA cycle, is decreased in the 26S proteasome-depleted cortexand may reﬂect mitochondrial dysfunction. We recently reported
that 26S proteasomal depletion in mouse brain neurones leads to the
formation of inclusions composed predominantly of morphologically
abnormal mitochondria with disrupted or disintegrated cristae [60]. A
spectrum of mitochondrial pathologies that may be associated with
oxidative stress has been described in human neurodegenerative
diseases and associated diseasemodels, including perturbed respiratory
chain function, mitochondrial dynamics and clearance [32,33,61].
Therefore, we suggest that mitochondrial dysfunction may be impor-
tant in the mechanism of oxidative stress and neurodegeneration
following 26S proteasome depletion.
Proteasome inhibition is known to induce endoplasmic reticulum
(ER) stress and activation of the unfolded protein response (UPR)
signaling pathways [62–64]. ER stress is associated with the production
of ROS from the ER as well as mitochondria and evidence of ER stress
has been shown in various human neurodegenerative diseases, such
as AD and PD [65–68]. Investigation of key mammalian ER
stress-induced proteins; the chaperone glucose-regulated protein 78
(GRP78), the transcription factor X-box binding protein-1 (XBP1),
protein disulphide isomerase (PDI) and the cell death mediator
CCAAT-enhancer-binding protein homologous protein (CHOP), showed
that neuronal 26S proteasomal depletion does not cause activation of
the UPR (Supplementary Fig. 3) [69,70]. Taken together, ER stress is
not an important source of ROS in this model.
Although we found evidence for increased oxidation of lipids
indicative of oxidative stress in the cortex following neuronal
26S proteasome depletion, protein oxidation was not increased.
Proteasome function is known to be important for the degradation
of oxidatively modiﬁed proteins [71–75]. Therefore, we may have
expected to ﬁnd increased protein oxidation following 26S
proteasome depletion in the mouse cortex due to increased oxida-
tive stress and/or decreased removal of oxidatively modiﬁed
proteins. However, in the heterogeneous population of cellular
proteasome complexes, the 26S proteasome has a relatively minor
role in the removal of oxidatively damaged proteins compared to
the 20S proteasome [72,73,76–78]. We previously showed that
inactivation of Psmc1 speciﬁcally disrupts 26S proteasome function;
assembly and activity of the 20S core proteolytic proteasome was
not affected [10]. Therefore, 20S proteasome function in Psmc1;
CaMKIIα-Cre neurones may be sufﬁcient to protect cells from protein
oxidative modiﬁcation. Alternatively, it is possible that the level of
protein oxidation was not sufﬁcient for detection in a mixed cell
population of targeted (CaMKIIα) and non-targeted neurones and
glia.
Different quantitative proteomic approaches will favor different
subpopulations of proteins. 2D-DIGE ﬂuorescence-based detection
provides high sensitivity that is linear over several orders of magni-
tude [79,80]. The signiﬁcant advantage of this technology is the ability
to multiplex using different ﬂuorescent cyanine dyes, providing
greater accuracy of quantitation over conventional 2D gel approaches
[79]. However, the percentage of lysine residues in proteins may
affect labeling efﬁciency and current in-gel digestion and mass spec-
trometers limit identiﬁcation of lesser abundant proteins detected
by 2D-DIGE [79]. Together with the well-known limitations of 2D
gel electrophoresis, i.e. hydrophobic proteins, dynamic range and
quantitative distribution issues, our study may miss some important
molecular players involved in the orchestration of cellular events
following neuronal 26S proteasomal depletion [79–81].
In conclusion, we reveal that oxidative stress may contribute
to the cellular events leading to neurodegeneration following UPS
dysfunction, providing a novel intersection between two prominent
hypotheses in disease pathogenesis. Increased astrocytic expression
of PRDX6 also reveals innovative information regarding the role of
neuronal–glial interactions and astrogliosis in neurodegeneration.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.07.002.
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